The Survival of Heart Transplant Recipients Using Cyclosporine and Everolimus Is Not Inferior to That Using Cyclosporine and Mycophenolate
Abstract Introduction Heart transplantation has become the best available therapy for patients with refractory end-stage heart failure. Cyclosporine (CsA) and mycophenolate mofetil (MMF) are the 2 FDA-approved drugs to prevent posttransplant acute rejection episodes. The purpose of this study was to...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2010-04, Vol.42 (3), p.938-939 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 939 |
|---|---|
| container_issue | 3 |
| container_start_page | 938 |
| container_title | Transplantation proceedings |
| container_volume | 42 |
| creator | Wang, S.-S Chou, N.-K Chi, N.-H Huang, S.-C Wu, I.-H Wang, C.-H Yu, H.-Y Chen, Y.-S Tsao, C.-I Ko, W.-J Shun, C.-T |
| description | Abstract Introduction Heart transplantation has become the best available therapy for patients with refractory end-stage heart failure. Cyclosporine (CsA) and mycophenolate mofetil (MMF) are the 2 FDA-approved drugs to prevent posttransplant acute rejection episodes. The purpose of this study was to evaluate the result of heart transplantation treated with CsA and everolimus (EVL), compared with that of patients treated with CsA and MMF. Materials and Methods From 2000 to 2009 heart transplantation was performed in 239 patients among whom we enrolled 93 patients with a serum creatinine values ≤2.8 mg/dL after informed written consents. The 2 arms were a CE group, who received EVL ( n = 46) CsA, and steroid ( n = 46), and a CM group who received MMF, CsA, and steroid ( n = 47). Results There was no operative mortality in either groups. The 1- and 5-year survivals of the CE group were 97.67 ± 2.22% and 80.23 ± 6.87%, versus the CM group, 97.72 ± 2.17% and 79.38 ± 7.62%, respectively. There was significant difference between the 2 groups. Conclusion Survival after heart transplantation under EVL or MMF plus CsA and steroid was good. The survival of patients under the regimen of EVL, CsA and, steroid was not inferior to that of subjects prescribed MMF, CsA and steroid up to 5 years. |
| doi_str_mv | 10.1016/j.transproceed.2010.03.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733933414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134510002861</els_id><sourcerecordid>733933414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-4cfe276c43fae0178d485bd8dbb697f4bc0eacf66c462bb5cf500244e04e1ace3</originalsourceid><addsrcrecordid>eNqNkt9qFDEUxoNY7Fp9BQmCeDXb_NuZWS8EWatdqAp2ex0ymRM362wyTTIL-wp96ma6WyyC4FUI-Z3z5XzfQegtJVNKaHm-maagXOyD1wDtlJH8QPiUEPYMTWhd8YKVjD9HE0IELSgXs1P0MsYNyXcm-At0yojghJH5BN2t1oCvh7CzO9Vhb_AlqJDw6kGgUy7hn6Btb8GliG-idb_wYq87H3sfrAOsXIsvdhB8Z7dDxMuIv_uEl85AsD7g5PFqrdK_Kr_tte_X4HynErxCJ0Z1EV4fzzN08-Vitbgsrn58XS4-XRValCIVQhtgVakFNwoIrepW1LOmrdumKeeVEY0moLQpM1GypplpM8vOCAFEAFUa-Bl6f-ibDbwdICa5tVFDl6cFP0RZcT7nXFCRyQ8HUgcfYwAj-2C3KuwlJXKMQm7k0yjkGIUkXGbBXPzmKDM02_z2WProfQbeHQEVtepMbqRt_MOxKk_HR-7zgYNsys5CkFHnPDS0NoBOsvX2__7z8a82urPOZuXfsIe48UNw2XZJZWSSyOtxecbdoXltWF1Sfg8OW8ZN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733933414</pqid></control><display><type>article</type><title>The Survival of Heart Transplant Recipients Using Cyclosporine and Everolimus Is Not Inferior to That Using Cyclosporine and Mycophenolate</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Wang, S.-S ; Chou, N.-K ; Chi, N.-H ; Huang, S.-C ; Wu, I.-H ; Wang, C.-H ; Yu, H.-Y ; Chen, Y.-S ; Tsao, C.-I ; Ko, W.-J ; Shun, C.-T</creator><creatorcontrib>Wang, S.-S ; Chou, N.-K ; Chi, N.-H ; Huang, S.-C ; Wu, I.-H ; Wang, C.-H ; Yu, H.-Y ; Chen, Y.-S ; Tsao, C.-I ; Ko, W.-J ; Shun, C.-T</creatorcontrib><description>Abstract Introduction Heart transplantation has become the best available therapy for patients with refractory end-stage heart failure. Cyclosporine (CsA) and mycophenolate mofetil (MMF) are the 2 FDA-approved drugs to prevent posttransplant acute rejection episodes. The purpose of this study was to evaluate the result of heart transplantation treated with CsA and everolimus (EVL), compared with that of patients treated with CsA and MMF. Materials and Methods From 2000 to 2009 heart transplantation was performed in 239 patients among whom we enrolled 93 patients with a serum creatinine values ≤2.8 mg/dL after informed written consents. The 2 arms were a CE group, who received EVL ( n = 46) CsA, and steroid ( n = 46), and a CM group who received MMF, CsA, and steroid ( n = 47). Results There was no operative mortality in either groups. The 1- and 5-year survivals of the CE group were 97.67 ± 2.22% and 80.23 ± 6.87%, versus the CM group, 97.72 ± 2.17% and 79.38 ± 7.62%, respectively. There was significant difference between the 2 groups. Conclusion Survival after heart transplantation under EVL or MMF plus CsA and steroid was good. The survival of patients under the regimen of EVL, CsA and, steroid was not inferior to that of subjects prescribed MMF, CsA and steroid up to 5 years.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2010.03.002</identifier><identifier>PMID: 20430209</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Actuarial Analysis ; Adult ; Aged ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Cyclosporine - adverse effects ; Cyclosporine - therapeutic use ; Drug Therapy, Combination ; Everolimus ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Heart Transplantation - immunology ; Heart Transplantation - mortality ; Humans ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Mycophenolic Acid - adverse effects ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - therapeutic use ; Pharmacology. Drug treatments ; Retrospective Studies ; Sirolimus - adverse effects ; Sirolimus - analogs & derivatives ; Sirolimus - therapeutic use ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Survival Rate ; Time Factors ; Tissue, organ and graft immunology</subject><ispartof>Transplantation proceedings, 2010-04, Vol.42 (3), p.938-939</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright (c) 2010 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-4cfe276c43fae0178d485bd8dbb697f4bc0eacf66c462bb5cf500244e04e1ace3</citedby><cites>FETCH-LOGICAL-c464t-4cfe276c43fae0178d485bd8dbb697f4bc0eacf66c462bb5cf500244e04e1ace3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2010.03.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3550,23930,23931,25140,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22701739$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20430209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, S.-S</creatorcontrib><creatorcontrib>Chou, N.-K</creatorcontrib><creatorcontrib>Chi, N.-H</creatorcontrib><creatorcontrib>Huang, S.-C</creatorcontrib><creatorcontrib>Wu, I.-H</creatorcontrib><creatorcontrib>Wang, C.-H</creatorcontrib><creatorcontrib>Yu, H.-Y</creatorcontrib><creatorcontrib>Chen, Y.-S</creatorcontrib><creatorcontrib>Tsao, C.-I</creatorcontrib><creatorcontrib>Ko, W.-J</creatorcontrib><creatorcontrib>Shun, C.-T</creatorcontrib><title>The Survival of Heart Transplant Recipients Using Cyclosporine and Everolimus Is Not Inferior to That Using Cyclosporine and Mycophenolate</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Introduction Heart transplantation has become the best available therapy for patients with refractory end-stage heart failure. Cyclosporine (CsA) and mycophenolate mofetil (MMF) are the 2 FDA-approved drugs to prevent posttransplant acute rejection episodes. The purpose of this study was to evaluate the result of heart transplantation treated with CsA and everolimus (EVL), compared with that of patients treated with CsA and MMF. Materials and Methods From 2000 to 2009 heart transplantation was performed in 239 patients among whom we enrolled 93 patients with a serum creatinine values ≤2.8 mg/dL after informed written consents. The 2 arms were a CE group, who received EVL ( n = 46) CsA, and steroid ( n = 46), and a CM group who received MMF, CsA, and steroid ( n = 47). Results There was no operative mortality in either groups. The 1- and 5-year survivals of the CE group were 97.67 ± 2.22% and 80.23 ± 6.87%, versus the CM group, 97.72 ± 2.17% and 79.38 ± 7.62%, respectively. There was significant difference between the 2 groups. Conclusion Survival after heart transplantation under EVL or MMF plus CsA and steroid was good. The survival of patients under the regimen of EVL, CsA and, steroid was not inferior to that of subjects prescribed MMF, CsA and steroid up to 5 years.</description><subject>Actuarial Analysis</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Cyclosporine - adverse effects</subject><subject>Cyclosporine - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Everolimus</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Heart Transplantation - immunology</subject><subject>Heart Transplantation - mortality</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - adverse effects</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Sirolimus - adverse effects</subject><subject>Sirolimus - analogs & derivatives</subject><subject>Sirolimus - therapeutic use</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Tissue, organ and graft immunology</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkt9qFDEUxoNY7Fp9BQmCeDXb_NuZWS8EWatdqAp2ex0ymRM362wyTTIL-wp96ma6WyyC4FUI-Z3z5XzfQegtJVNKaHm-maagXOyD1wDtlJH8QPiUEPYMTWhd8YKVjD9HE0IELSgXs1P0MsYNyXcm-At0yojghJH5BN2t1oCvh7CzO9Vhb_AlqJDw6kGgUy7hn6Btb8GliG-idb_wYq87H3sfrAOsXIsvdhB8Z7dDxMuIv_uEl85AsD7g5PFqrdK_Kr_tte_X4HynErxCJ0Z1EV4fzzN08-Vitbgsrn58XS4-XRValCIVQhtgVakFNwoIrepW1LOmrdumKeeVEY0moLQpM1GypplpM8vOCAFEAFUa-Bl6f-ibDbwdICa5tVFDl6cFP0RZcT7nXFCRyQ8HUgcfYwAj-2C3KuwlJXKMQm7k0yjkGIUkXGbBXPzmKDM02_z2WProfQbeHQEVtepMbqRt_MOxKk_HR-7zgYNsys5CkFHnPDS0NoBOsvX2__7z8a82urPOZuXfsIe48UNw2XZJZWSSyOtxecbdoXltWF1Sfg8OW8ZN</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Wang, S.-S</creator><creator>Chou, N.-K</creator><creator>Chi, N.-H</creator><creator>Huang, S.-C</creator><creator>Wu, I.-H</creator><creator>Wang, C.-H</creator><creator>Yu, H.-Y</creator><creator>Chen, Y.-S</creator><creator>Tsao, C.-I</creator><creator>Ko, W.-J</creator><creator>Shun, C.-T</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100401</creationdate><title>The Survival of Heart Transplant Recipients Using Cyclosporine and Everolimus Is Not Inferior to That Using Cyclosporine and Mycophenolate</title><author>Wang, S.-S ; Chou, N.-K ; Chi, N.-H ; Huang, S.-C ; Wu, I.-H ; Wang, C.-H ; Yu, H.-Y ; Chen, Y.-S ; Tsao, C.-I ; Ko, W.-J ; Shun, C.-T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-4cfe276c43fae0178d485bd8dbb697f4bc0eacf66c462bb5cf500244e04e1ace3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Actuarial Analysis</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Cyclosporine - adverse effects</topic><topic>Cyclosporine - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Everolimus</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Heart Transplantation - immunology</topic><topic>Heart Transplantation - mortality</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - adverse effects</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Sirolimus - adverse effects</topic><topic>Sirolimus - analogs & derivatives</topic><topic>Sirolimus - therapeutic use</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Tissue, organ and graft immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, S.-S</creatorcontrib><creatorcontrib>Chou, N.-K</creatorcontrib><creatorcontrib>Chi, N.-H</creatorcontrib><creatorcontrib>Huang, S.-C</creatorcontrib><creatorcontrib>Wu, I.-H</creatorcontrib><creatorcontrib>Wang, C.-H</creatorcontrib><creatorcontrib>Yu, H.-Y</creatorcontrib><creatorcontrib>Chen, Y.-S</creatorcontrib><creatorcontrib>Tsao, C.-I</creatorcontrib><creatorcontrib>Ko, W.-J</creatorcontrib><creatorcontrib>Shun, C.-T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, S.-S</au><au>Chou, N.-K</au><au>Chi, N.-H</au><au>Huang, S.-C</au><au>Wu, I.-H</au><au>Wang, C.-H</au><au>Yu, H.-Y</au><au>Chen, Y.-S</au><au>Tsao, C.-I</au><au>Ko, W.-J</au><au>Shun, C.-T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Survival of Heart Transplant Recipients Using Cyclosporine and Everolimus Is Not Inferior to That Using Cyclosporine and Mycophenolate</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>42</volume><issue>3</issue><spage>938</spage><epage>939</epage><pages>938-939</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Introduction Heart transplantation has become the best available therapy for patients with refractory end-stage heart failure. Cyclosporine (CsA) and mycophenolate mofetil (MMF) are the 2 FDA-approved drugs to prevent posttransplant acute rejection episodes. The purpose of this study was to evaluate the result of heart transplantation treated with CsA and everolimus (EVL), compared with that of patients treated with CsA and MMF. Materials and Methods From 2000 to 2009 heart transplantation was performed in 239 patients among whom we enrolled 93 patients with a serum creatinine values ≤2.8 mg/dL after informed written consents. The 2 arms were a CE group, who received EVL ( n = 46) CsA, and steroid ( n = 46), and a CM group who received MMF, CsA, and steroid ( n = 47). Results There was no operative mortality in either groups. The 1- and 5-year survivals of the CE group were 97.67 ± 2.22% and 80.23 ± 6.87%, versus the CM group, 97.72 ± 2.17% and 79.38 ± 7.62%, respectively. There was significant difference between the 2 groups. Conclusion Survival after heart transplantation under EVL or MMF plus CsA and steroid was good. The survival of patients under the regimen of EVL, CsA and, steroid was not inferior to that of subjects prescribed MMF, CsA and steroid up to 5 years.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>20430209</pmid><doi>10.1016/j.transproceed.2010.03.002</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2010-04, Vol.42 (3), p.938-939 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733933414 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Actuarial Analysis Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Cyclosporine - adverse effects Cyclosporine - therapeutic use Drug Therapy, Combination Everolimus Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Fundamental immunology Heart Transplantation - immunology Heart Transplantation - mortality Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Male Medical sciences Middle Aged Mycophenolic Acid - adverse effects Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use Pharmacology. Drug treatments Retrospective Studies Sirolimus - adverse effects Sirolimus - analogs & derivatives Sirolimus - therapeutic use Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Survival Rate Time Factors Tissue, organ and graft immunology |
| title | The Survival of Heart Transplant Recipients Using Cyclosporine and Everolimus Is Not Inferior to That Using Cyclosporine and Mycophenolate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T16%3A01%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Survival%20of%20Heart%20Transplant%20Recipients%20Using%20Cyclosporine%20and%20Everolimus%20Is%20Not%20Inferior%20to%20That%20Using%20Cyclosporine%20and%20Mycophenolate&rft.jtitle=Transplantation%20proceedings&rft.au=Wang,%20S.-S&rft.date=2010-04-01&rft.volume=42&rft.issue=3&rft.spage=938&rft.epage=939&rft.pages=938-939&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2010.03.002&rft_dat=%3Cproquest_cross%3E733933414%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733933414&rft_id=info:pmid/20430209&rft_els_id=S0041134510002861&rfr_iscdi=true |